Association of glycoprotein IIb/IIIa inhibitors and long-term survival following administration during percutaneous coronary intervention for acute myocardial infarction

By Berger Jeffrey   Brown David  

Journal of Thrombosis and Thrombolysis, Vol. 21, Iss. 3, 2006-06 ,pp. : 229-234

Springer Publishing Company

Access to resources Recommend Favorite

Glycoprotein IIb/IIIa inhibitor associated severe thrombocytopenia in patients with coronary artery disease: Clinical course and outcomes

By Viswanathan Girish   Kidambi Ananth   Nelson Adam   Mayurathan Gnanamoorthy   Hardy John   Kesteven Patrick   Zaman Azfar  

Platelets, Vol. 23, Iss. 3, 2012-05 ,pp. : 224-228

Informa Healthcare

Access to resources Recommend Favorite

Impact of diabetes on long-term outcome in STEMI patients undergoing primary angioplasty with glycoprotein IIb–IIIa inhibitors and BMS or DES

By Luca Giuseppe   Sauro Rosario   Varricchio Attilio   Capasso Michele   Lanzillo Tonino   Manganelli Fiore   Mariello Ciro   Siano Francesco   Carbone Giannignazio   Pagliuca Maria   Rosato Giuseppe   Lorenzo Emilio  

Journal of Thrombosis and Thrombolysis, Vol. 30, Iss. 2, 2010-08 ,pp. : 133-141

Springer Publishing Company

Access to resources Recommend Favorite

Successful recanalization of an occluded coronary artery by percutaneous coronary intervention, systemic administration of tirofiban, a glycoprotein IIb/IIIa inhibitor, and intracoronary thrombolysis with alteplase

By Meyners W.  

Zeitschrift für Kardiologie, Vol. 93, Iss. 5, 2004-05 ,pp. : 407-412

Springer Publishing Company

Access to resources Recommend Favorite

The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary

By  

Current Cardiology Reviews, Vol. 4, Iss. 4, 2008-11 ,pp. : 293-299

Bentham Science Publishers

Access to resources Recommend Favorite